TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:11
ARCA biopharma Inc. ( ABIO ) https://www.arcabio.com
1.71USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-15.76%
ABIO
SPY
32.74%
-53.53%
ABIO
SPY
92.93%
-74.57%
ABIO
SPY
224.41%
-99.25%
ABIO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
25.81
-11.34
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.33
0.00
0.70
-19.45
0.00
1.51
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.0142
-19.01
-19.57
1.54
Other Earnings and Cash Flow Stats:
ARCA biopharma Inc. ( ABIO ) Net Income TTM ($MM) is -5.23
ARCA biopharma Inc. ( ABIO ) Operating Income TTM ($MM) is -7.83
ARCA biopharma Inc. ( ABIO ) Owners' Earnings Annual ($MM) is 0.00
ARCA biopharma Inc. ( ABIO ) Current Price to Owners' Earnings ratio is 0.00
ARCA biopharma Inc. ( ABIO ) EBITDA TTM ($MM) is -7.72
ARCA biopharma Inc. ( ABIO ) EBITDA Margin is 0.00%
Capital Allocation:
ARCA biopharma Inc. ( ABIO ) has paid 0.00 dividends per share and bought back -0.091000000000001 million shares in the past 12 months
ARCA biopharma Inc. ( ABIO ) has reduced its debt by 0.103 million USD in the last 12 months
Capital Structure:
ARCA biopharma Inc. ( ABIO ) Interest-bearing Debt ($MM) as of last quarter is 0
ARCA biopharma Inc. ( ABIO ) Annual Working Capital Investments ($MM) are -1
ARCA biopharma Inc. ( ABIO ) Book Value ($MM) as of last quarter is 37
ARCA biopharma Inc. ( ABIO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ARCA biopharma Inc. ( ABIO ) has 37 million in cash on hand as of last quarter
ARCA biopharma Inc. ( ABIO ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ARCA biopharma Inc. ( ABIO ) has 14 common shares outstanding as of last quarter
ARCA biopharma Inc. ( ABIO ) has 0 million USD of preferred stock value
Academic Scores:
ARCA biopharma Inc. ( ABIO ) Altman Z-Score is 11.94 as of last quarter
ARCA biopharma Inc. ( ABIO ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
ARCA biopharma Inc. ( ABIO ) largest shareholder is owning shares at 0.00 ($MM) value
Fund Lp Funicular(an insider) Bought 64851 shares of ARCA biopharma Inc. ( ABIO ) for the amount of $150454.32 on 2022-05-25
1.02% of ARCA biopharma Inc. ( ABIO ) is held by insiders, and 50.61% is held by institutions
ARCA biopharma Inc. ( ABIO ) went public on 1997-08-08
Other ARCA biopharma Inc. ( ABIO ) financial metrics:
FCF:-7.26
Unlevered Free Cash Flow:-5.52
EPS:-0.39
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-15.39
Beta:1.54
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ARCA biopharma Inc. ( ABIO ) :
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.